New data from novel adjuvant system

RNS Number : 0772M

Allergy Therapeutics PLC

10 October 2016

 



10 October 2016

Allergy Therapeutics plc

("Allergy Therapeutics" or the "Company")

Allergy Therapeutics presents enhanced efficacy data in a malaria vaccine model

with its novel adjuvant system

Data to be presented today at the World Vaccine Congress demonstrates significant improvements in effective infectious disease applications using Bencard Adjuvant Systems technology

Allergy Therapeutics (AIM:AGY), the fully integrated pharmaceutical company specialising in allergy vaccines, together with its wholly-owned division, Bencard Adjuvant Systems (BAS), which specialises in developing and optimising adjuvants for prophylactic vaccination and allergen immunotherapy, announces new data using a novel adjuvant system that shows enhancement of efficacy in a malaria vaccine model. These results will be presented today at the World Vaccine Congress in Barcelona, Spain at 16:00 CET.

In an oral session entitled: "Platform technologies to emerging pathogens", Allergy Therapeutics' principal scientist, Dr Matthew Heath, PhD, in conjunction with the Jenner Institute, University of Oxford, will present new information on adjuvant activity and enhanced efficacy in a candidate vaccine formulation against Plasmodium vivax (malaria). Microcrystalline tyrosine (MCT), the aluminium-free depot adjuvant used in Allergy Therapeutics' successfully marketed and rapidly growing Pollinex Quattro® immunotherapy product, was shown to elicit high, sustained antibody titres in a preclinical model and demonstrated increased protective efficacy compared to existing adjuvants.

Furthermore, Dr Heath will discuss how MCT has synergistic effects when coupled with Virus Like Particles (VLP) to create a combined and unique Adjuvant System, AdSys-VcT. The data indicated a significant increase in specific antibodies and other immune parameters indicative of protective efficacy compared to aluminium salts. The potential for this novel adjuvant system in infectious disease applications was concluded to be highly significant.

Allergy Therapeutics has been pioneering the development of novel adjuvant systems with the combination of MCT and monophosphoryl lipid A (MPL) in allergy immunotherapy, allowing for the successful introduction of the concept of ultra-short course immunotherapy in the allergy vaccines market.

BAS, the fully owned Allergy Therapeutics division specialising in adjuvant systems, has signed a Memorandum of Understanding with Saiba GmbH, the Swiss-based vaccines company, to develop new applications of its novel adjuvant system, AdSys-VcT, for use in prophylactic vaccination and food allergy immunotherapy. BAS has a portfolio of adjuvants with certain exclusive rights.

Dr Murray Skinner, Chief Scientific Officer of Allergy Therapeutics, said: "Our positive data on adjuvant development is great news in an environment where organisations such as the US National Institutes of Health describe a significant unmet need for adjuvants suitable for use in combination with the growing number of emerging and evolving infectious disease targets¹. These data support our belief that Bencard Adjuvant Systems has a potentially wide range of applications and we look forward to further results and collaborations, such as this one, in infectious diseases."

Manuel Llobet, Chief Executive Officer of Allergy Therapeutics, commented: "It is exciting to announce that our portfolio of adjuvants can be combined to create adjuvant systems that deliver optimised immunotherapy in both allergy indications and infectious disease applications. Our strategy for growth with Bencard Adjuvant Systems focuses on extending the use of MCT with novel adjuvants to create novel adjuvant systems capable of increasing the effectiveness of new and existing vaccines with unmet needs, and or new and emerging infectious diseases that require an effective adjuvant system like AdSys-VcT."

References

¹ Mullard, A. NIAID amps up vaccine adjuvant work. Nature Reviews Drug Discovery. 2014. 13:803.

ENDS

For further information, please contact:

Allergy Therapeutics

[phone]

Manuel Llobet, Chief Executive Officer

Nick Wykeman, Finance Director

Panmure Gordon

[phone]

Freddy Crossley / Duncan Monteith, Corporate Finance

Tom Salvesen, Corporate Broking

Consilium Strategic Communications

[phone]

Mary-Jane Elliott / Ivar Milligan / Matthew Neal / Laura Thornton

[e-mail]

Note to editors:

About Allergy Therapeutics

Allergy Therapeutics is an international specialty pharmaceutical company focussed on the treatment and diagnosis of allergic disorders including immunotherapy vaccines that cure disease.  The Company sells proprietary products and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries.

Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with MHRA-approved manufacturing facilities.  The Company employs c.420 employees and is listed on the London Stock Exchange (AIM:AGY). For more information, please see www.allergytherapeutics.com.

About Bencard Adjuvant Systems

Bencard Adjuvant Systems (BAS) is a division of Allergy Therapeutics UK. Located in UK, BAS specialises in developing and optimising adjuvants for vaccines against infectious diseases and allergen immunotherapy.  The team at BAS are committed to engaging in long-term partnerships with those who require BAS's patented platform of adjuvant technologies to enable successful vaccine or immunotherapy development.  For more information, please contact www.bencard-as.com.

 

END

 

 

MSCFKLLBQBFFFBL